Table 4.
Phase II and III clinical trials studying Jak inhibitors in psoriasis.
| Drug name | Identifier | Status | Phase, administration | Enrollment | Duration |
|---|---|---|---|---|---|
| Tofacitinib | NCT01710046 | Completed (115) | IIa, per os | 12 | 12-week |
| NCT00678210 | Completed (116) | IIb, per os | 197 | 12-week | |
| NCT01241591 | Completed (117) | III, per os | 1,101 | 12-week non-inferiority trial compared to etanercept | |
| NCT01519089 | Completed (118) | III, per os | 95 | 52-week evaluating long-term safety | |
| NCT01186744 | Completed (119) | III, per os | 666 | 56-week withdrawal and retreatment study | |
| NCT01276639 and NCT01309737 | Completed (120) | III, per os | 901 and 960 | 52-week | |
| NCT01815424 | Completed (121) | III, per os | 266 | 52-week | |
| NCT01163253 | Terminated as it met its objectives (122) | III, per os | 2,867 | median duration 35.6 months open-label extension study who completed qualifying phase II/III studies | |
| NCT01831466 | Completed (123) | IIb, topical | 430 | 12-week | |
| Ruxolitinib | NCT00820950 | Completed (124) | II, topical | 29 | 28-day |
| NCT00778700 | Completed, no results available | II, topical | 199 | 12-week | |
| Baricitinib | NCT01490632 | Completed (125) | IIb, per os | 271 | 12-week |
| Abrocitinib | NCT02201524 | Terminated (126) | II, per os | 59 | 4-week terminated due to changes in sponsors development priorities |
| PF-06700841 | NCT02969018 | Completed | IIa, per os | 212 | 12-week, results online |
| NCT03850483 | Not yet recruiting | IIb, topical | 240 | 12-week | |
| Itacitinib | NCT01634087 | Completed (127) | II, per os | 50 | 28-day |
| BMS986165 | NCT02931838 | Completed (128) | II, per os | 267 | 12-week |
| NCT03624127 and NCT03611751 | Recruiting | III, per os | 600 and 1,000 | Non-inferiority study compared to apremilast | |
| Solcitinib | NCT01782664 | Completed (129) | IIa, per os | 68 | 12-week |